FibroGen
Max Ma is an experienced IT professional with a robust background in technology management and account management. Currently serving as IT Manager at FibroGen, Inc. since August 2014, Max previously held positions as Account Manager at Accenture from November 2010 to August 2014, IT Services Manager at Lenovo from August 2009 to November 2010, and Lead IT Specialist at HP from August 2006 to August 2009. Max Ma earned a Bachelor's degree in Electrical and Electronics Engineering from Shenyang University of Technology between 1997 and 2001.
This person is not in any offices
FibroGen
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company's most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.